Clinical Trials with an Anti-CD25 Ricin A-Chain Experimental and Immunotoxin (RFT5-SMPT-dgA) in Hodgkin's Lymphoma

References

• De Vita V.T., Molloy Hubbard S. Hodgkin's lymphoma. New Engl. J. Med. 1983; 328: 560–565
   Google Scholar
• Longo I.L., Young R.C., Wesley M. Twenty years of MOPP therapy for Hodgkin's lymphoma. J. Clin. Oncol 1986; 4: 1295–1306
   PubMed Web of Science ®Google Scholar
• Riethmüller G., Schneider-Gädicke E., Schlimok G., Schmiegel W., Raab R., Höffken K., Gruber R., Pichlmaier H., Hirche H., Pichlmayr R., Buggisch P., Witte R., and the German Cancer Aid 17-1A Study Group. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes'C colorectal carcinoma. Lancet 1994; 343: 1177–1183
   PubMed Web of Science ®Google Scholar
• J Ro D.C., Griffin J.D., Belvin M., Blättler W.A., Lambert J.M., Ritz J. Anti-My9-blocked ricin: An immunotoxin for selective targeting of acute myeloid leukemia cells. Blood 1991; 77: 2404–2412
   PubMed Web of Science ®Google Scholar
• Gribben J.G., Freedman A.S., Neuberg D., Roy D.C., Blake K.W., Woo S.D., Grossbard M.L., Rabinowe S.N., Coral F., Freeman G.L, Ritz J., Nadler L.M. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N. Engl. J. Med. 1991; 325: 1525–1533
   PubMed Web of Science ®Google Scholar
• Simonsson B. Treatment of minimal residual disease in acute myelogenous leukemia (AML): focus on immunotherapeutic options. Leukemia 1996; 10 Suppl 2: 44–45
   Web of Science ®Google Scholar
• Mitchell M.S. Active specific immunotherapy of melanoma. Br. Med. Bull 1995; 51(3)631–645
   PubMed Web of Science ®Google Scholar
• Grossbard M.L., Gribben J.G., Freedman A.S., Lambert J., Kinsella J., Rabinowe S., Eliseo L., Taylor J., Blatter W., Epstein C., Nadler L. Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood 1993; 81: 2263–2271
   PubMed Web of Science ®Google Scholar
• J Schnell R., Barth S., Diehl V., Engert A. Hodgkin's disease. Future treatment strategies: fact or fiction. Baillieres Clinical Haematology, V. Diehl, 1996; 573–593
   Google Scholar
• Hsu S.M., Jaffe E.S. Leu M1 and peanut agglutinin stain the neoplastic cells of Hodgkin's lymphoma. Am. J. Clin. Pathol 1984; 82: 29–32
   PubMed Web of Science ®Google Scholar
• Hsu S.M., Ho Y.S., Hsu P.L. Effect of monoclonal antibodies anti-2H9, anti-IRac, and anti-HeFi-1 on the surface antigens of Reed-Sternberg cells. J. Nat. Cancer Inst. 1987; 79: 1091–1097
   PubMed Web of Science ®Google Scholar
• Stein H., Mason D.Y., Gerdes J., O'Conner N., Wainscoat J., Pallesen G., Gatter K., Falini B., Delsol G., Lemke H., Schwarting R., Lennert K. The expression of the Hodgkin's-disease-associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Sternberg-Reed cells and histocytic malignancies are derived from activated lymphoid cells. Blood 1985; 66: 848–858
   PubMed Web of Science ®Google Scholar
• Agnarsson B.A., Kadin M.E. The immunophenotype of Reed-Sternberg cells. A study of 50 cases of Hodgkin's lymphoma using fixed frozen tissue. Cancer 1989; 63: 2083–2087
   PubMed Web of Science ®Google Scholar
• Casey T.T., Olson S.J., Cousar J.B., Collins R.D. Immunophenotypes of Reed-Sternberg cells: a study of 19 cases of Hodgkin's lymphoma in plastic-embedded sections. Blood 1989; 74: 5042–5046
   Web of Science ®Google Scholar
• Kennedy I.C., Hart D.N., Colls B.M. Nodular sclerosing, mixed cellularity and lymphocyte-depleted variants of Hodgkin's lymphoma are probable dendritic cell malignancies. Clin. Exp. Immunol. 1989; 76: 324–331
   PubMed Web of Science ®Google Scholar
• Delabie J., Ceuppens J.L., Vandenberghe P., de Boer M., Coorevits L., de Wolf-Peeters C. The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's lymphoma and contributes to the stimulating capacity of Hodgkin's lymphoma-derived cell lines. Blood 1993; 82: 2845–2852
   PubMed Web of Science ®Google Scholar
• Taniguchi T., Minami Y. The IL-2/IL-2 receptor system: a current overview. Cell 1993; 73: 5–8
   PubMed Web of Science ®Google Scholar
• Kreitman R.J., Pastan I. Recombinant single-chain immunotoxins against T- and B-cell leukemias. Leuk. Lymph. 1994; 13: 1–10
   PubMed Web of Science ®Google Scholar
• Strauchen J.A., Breakstone B.A. IL-2 receptor expression in human lymphoid lesions. Immunohistochemical study of 166cases.Am. J. Pathol. 1987; 126: 506–512
   Web of Science ®Google Scholar
• Till M., May R.D., Uhr J.W., Thorpe P.E., Vitetta E.S. An assay that predicts the ability of monoclonal antibodies to form potent ricin A chain-containing immunotoxins. Cancer Res. 1988; 48: 1119–1123
   PubMed Web of Science ®Google Scholar
• Diehl V., Kirchner H.H., Schaadt M., Fonatsch C., Stein H., Gerdes J., Boie C. Hodgkin's disease: establishment and characterization of four in vitro cell lines. J. Cancer Res. Clin. Oncol. 1981; 101: 111–124
   PubMed Web of Science ®Google Scholar
• Casellas P., Brown J.P., Gros O., Gros P., Hellstrom I., Jansen F.K., Poncelet P., Roncucci R., Vidal H., Hellstrom K.E. Human melanoma cells can be killed in vitro by an immunotoxin specific for melanoma-associated antigen p97. Int. J. Cancer 1981; 30: 437–443
   Web of Science ®Google Scholar
• Engert A., Martin G., Amlot P., Wijdenes J., Diehl V., Thorpe P. Immunotoxins constructed with anti-CD25 monoclonal antibodies and deglycosylated ricin A-chain have potent anti-tumour effects against human Hodgkin cells in vitro and solid Hodgkin tumours in mice. Int. J. Cancer 1991; 49: 450–456
   PubMed Web of Science ®Google Scholar
• Winkler U., Gottstein C, Schön G., Kapp U., Wolf J., Hansmann M.L., Bohlen H., Thorpe P., Diehl V., Engert A. Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxins. Blood 1994; 83: 466–475
   PubMed Web of Science ®Google Scholar
• Engert A., Diehl V., Schnell R., Radszuhn A., Hatwig M.T., Drillich S., Schön G., Bohlen H., Tesch H., Hansmann M.L., Barth S., Schindler J., Ghetie V., Uhr J., Vitetta E. A Phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood 1997; 89(2)403–410
   PubMed Web of Science ®Google Scholar
• Vitetta E.S., Stone M., Amlot P., Fay J., May R., Till M., Newman J., Clark P., Collins R., Cunningham D., Ghetie V., Uhr J., Thorpe P. Phase-I immunotoxin trial in patients with B-cell lymphoma. Cancer Res. 1991; 51: 4052–4058
   PubMed Web of Science ®Google Scholar
• Amlot P., Stone M.J., Cunningham D., Fay J., Newman J., Collins R., May R., McCarthy M., Richardson J., Ghetie V., Ramillo O., Thorpe P., Uhr J., Vitetta E.S. A Phase-I study of an anti-CD22-deglycosylated ricin A-chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 1993; 82: 2624–2633
   PubMed Web of Science ®Google Scholar
• Sausville E.A., Headlee D., Stetler-Stevenson M., Jaffe E.S., Solomon D., Figg W.D., Herdt J., Kopp W.C, Rager H., Steinberg S.M., Ghetie V., Schindler J., Uhr J.W., Wittes R.E., Vitetta E.S. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: A Phase-1 study. Blood 1995; 85: 3457–3465
   PubMed Web of Science ®Google Scholar
• Stone M.J., Sausville E.A., Fay J.W., Headlee D., Collins R.H., Figg W.D., Stetler-Stevenson JainM.V., Jaffe E.S., Solomon D., Lush R.M., Senderowilz A., Ghetie V., Schindler J., Uhr J.W., Vitetta E.S. A Phase-1 study of bolus vs. continuous infusion of the anti-CD19 immunotoxin, IgG-HL37-dgA in patients with B cell lymphoma. Blood 1996; 88(4)1188–1197
   PubMed Web of Science ®Google Scholar
• Vitetta E.S., Thorpe P.E., Uhr J.W. Immunotoxins: magic bullets or misguided missiles?. Immunol. Today 1993; 14: 252–259
   PubMedGoogle Scholar
• Byers V.S., Baldwin R.W. Rationale for clinical use of immunotoxins in cancer and autoimmune diseases. Sent. Cell Biol. 1991; 2: 59–70
   PubMedGoogle Scholar
• Durrant L.G., Byers V.S., Scannon P.J., Rodvien R., Grant K., Robins R.A., Marksman R.A., Baldwin R.W. Humoral immune resonses to XMMCO-791-RTA immunotoxins in colorectal cancer patients. Clin. Exp. Immunol. 1989; 75: 258–264
   PubMed Web of Science ®Google Scholar
• Junghans R.P., Waldmann T.A. Metabolism of TAC (IL2Rα): Physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding. J. Exp. Med. 1996; 185: 1587–1602
   Web of Science ®Google Scholar
• Kreitman R.J., Chaudhary V.K., Kozak R.W., FitzGerald D.J.P., Waldmann T.A., Pastan I. Recombinant toxins containing the variable domains of the anti-TAC monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocytic leukemia. Blood 1992; 80: 2344–2352
   PubMed Web of Science ®Google Scholar
• Kreitman R.J., Chaudhary V.K., Waldmann T.A., Hanchard B., Cranston B., FitzGerald D.J.P., Pastan I. Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or Diphteria toxin toward lymphocytes from patients with adult T-cell leukemia. Leukemia 1993; 7: 553–562
   PubMed Web of Science ®Google Scholar
• Foss F.M., Borkowski T.A., Gilliom M., Stetler-Stevenson M.A., Jaffe E.S., Figg W.D., Tompkins A., Bastian A., Nylen P., Woodworth T., Udey M.C., Sausville E.A. Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: Correlation of activity and interleukin-2 receptor expression in a Phase-II study. Blood 1994; 84: 1765–1774
   PubMed Web of Science ®Google Scholar
• Foss F.M., Nichols J., Parker K. Seragen Lymphoma Study Group. Phase-I/II trial of DAB389IL-2 in patients with NHL, HL and CTCL. Fourth International Symposium on Immunotoxins. 1995; 159A
   Google Scholar
• Williams D.P., Parker K., Bacha P., Bishai W., Borowksi M., Genbauffe F., Strom T.B., Murphy J.R. Diphtheria toxin receptor binding domain substitution with interleukin-2: Genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Prot Eng 1987; 1: 493–498
   PubMedGoogle Scholar
• LeMaistre C.F., Craig F.E., Meneghetti C.M., McMullin B., Parker K., Reuben J., Boldt D.H., Rosenblum M., Woodworth T. Phase-I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancers. Cancer Res 1993; 53: 3930–3934
   PubMed Web of Science ®Google Scholar
• LeMaistre C.F., Meneghetti C, Rosenblum M., Reuben J., Parker K., Shaw J., Deisseroth A., Woodworth T., Parkinson D.R. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB48JL-2) in hematologic malignancies expressing the IL-2 receptor. Blood 1992; 79: 2547–2554
   PubMed Web of Science ®Google Scholar
• Tepler I., Schwartz G., Parker K., Charette J., Kadin M.E., Woodworth T.G., Schnipper L.E. Phase-I trial of an interleukin-2 fusion toxin (DAB486IL-2) in hematologic malignancies: Complete response in a patient with Hodgkin's disease refractory to chemotherapy. Cancer 1994; 73: 1276–1285
   PubMed Web of Science ®Google Scholar
• Schwab U., Stein H., Gerdes J., Kirchner H., Schaadt M., Diehl V. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's lymphoma and a subset of normal lymphoid cells. Nature 1982; 299: 65–67
   PubMed Web of Science ®Google Scholar
• Tazzari P.L., Bolognesi A., de Totero D., Falini B., Lemoli R.M., Soria M.R., Pileri S., Gobbi M., Stein H., Flenghi L., Martelli M.F., Stirpe F. Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's lymphoma and CD30+ lymphoma: in vitro evaluation. Br. J. Haematol. 1992; 81: 203–211
   PubMed Web of Science ®Google Scholar
• Pasqualucci L., Wasik M., Teicher B.A., Flenghi L., Bolognesi A., Stirpe F., Polito L., Falini B., Kadin ME. Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma. Blood 1995; 85: 2139–2146
   PubMed Web of Science ®Google Scholar
• Falini B., Bolognesi A., Flenghi L., Tazzari P.L., Broe M.K., Stein H., Durkop H. Response of refractory Hodgkin's lymphoma to monoclonal anti-CD30 immunotoxin. Lancet 1992; 339: 1195–1196
   PubMed Web of Science ®Google Scholar
• Falini B., Pasqualucci L., Flenghi L., Bolognesi A., Kadin M., Stein H., Martinelli M.F., Stirpe F. Anti-CD30 immunotoxins: experimental and clinical studies. Abstracts of the Fourth International Symposium on Immunotoxins. 1995; 160
   Google Scholar
• Engert A., Burrows F., Jung W., Tazzari P.L., Stein H., Pfreundschuh M., Diehl V., Thorpe P. Evaluation of ricin A-chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's lymphoma. Cancer Res. 1990; 50: 84–88
   PubMed Web of Science ®Google Scholar
• Engert A., Martin G., Pfreundschuh M., Amlot P., Hsu S.M, Diehl V., Thorpe P.E. Antitumor effects of ricin A-chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's lymphoma tumors in mice. Cancer Res. 1990; 50: 2929–2935
   PubMed Web of Science ®Google Scholar
• Horn-Lohrens O., Tiemann M., Lange H., Kobarg J., Hafner M., Hansen H., Sterry W., Parwaresch R.M., Lemke H. Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4). In. J. Cancer 1995; 60: 539–544
   PubMed Web of Science ®Google Scholar
• Schnell R., Linnartz C., Schön G., Katouzi A., Bohlen H., Horn-Lohrens O., Parwaresch R., Diehl V., Lemke H., Engert A. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen. Int. J. Cancer 1995; 63: 238–244
   PubMed Web of Science ®Google Scholar
• Engert A., Gottstein C, Bohlen H., Winkler U., Schön G., Manske O., Schnell R., Diehl V., Thorpe P. Cocktails of ricin A-chain immunotoxins against different antigens of Hodgkin and Sternberg-Reed cells have superior anti-tumor effects against H-RS cells in vitro and solid Hodgkin tumors in mice. Int. J. Cancer 1995; 63: 304–309
   PubMed Web of Science ®Google Scholar
• Katz F.E., Janossy G., Cumber A., Ross W., Blacklock H.A., Tax W., Thorpe P.E. Elimination of T cells from human peripheral blood and bone marrow using a cocktail of three anti-T cell immunotoxins. Brit. J. Haematol. 1987; 67: 407–411
   PubMed Web of Science ®Google Scholar
• Ghetie M.A., Tucker K., Richardson L, Uhr J.W., Vitetta E.S. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD 19 antibody or an anti-CD19 immunotoxin. Blood 1992; 80: 2315–2320
   PubMed Web of Science ®Google Scholar